Research progress of cyclooxygenase-2 in the treatment of esophageal malignant tumors

Sha Chuang,Li Zhongcheng
DOI: https://doi.org/10.3760/j.issn.1673-4777.2023.04.027
2023-01-01
Abstract:Esophageal malignant tumors are currently the eighth largest malignant tumors in the world. In recent years, the molecular targeting researches on esophageal malignant tumors are not only focused on tyrosine kinase inhibitors or anti-angiogenic targeted therapy, but also on the high expression of cyclooxygenase, especially cyclooxygenase-2 subtype, in esophageal malignant tumors. Amount of studies confirmed that the high expression of cyclooxygenase-2 is closely related to the pathogenesis of esophageal malignant tumors. The feasibility of using selective cyclooxygenase-2 targeted inhibitors in the treatment of esophageal malignant tumors has become increasingly prominent. This article reviews the research progress of cyclooxygenase-2 and its typical targeted inhibitors in the treatment of esophageal malignant tumors, in order to provide reference for the treatment of patients with esophageal malignant tumors.
What problem does this paper attempt to address?